Introduction
The treatment of hypertension has resulted in a change in the incidence of the major causes of death attributable to this condition. There has been a fall in the percentage of patients dying of cerebrovascular disease, renal failure and heart failure but an increase in the numbers dying from coronary artery disease (Breckenridge, Dollery and Parry, 1970) . It is not clear from the available data whether or not the increase in the incidence of deaths from coronary artery disease is due to the reduction in deaths from the other causes or whether hypotensive therapy itself may be more directly responsible.
Numerous epidemiological studies have shown that blood lipid levels correlate strongly with the development of clinical ischaemic heart disease (IHD). The relationship between IHD and serum cholesterol extends throughout the entire spectrum of serum cholesterol values. Lipid metabolism and blood lipid levels are influenced to a significant extent by the sympathetic nervous system and circulating catecholamines (Havel, 1968 Tarlow, 1971) . The fractions were quantitated visually. The concentration of S, M and L particles was estimated nephelometrically as described by Stone and Thorpe (1966) . 'Lipoprotein profiles' were based on the classification of Fredrickson but taking the S-M-L scores into account (Fredrickson, (Lundbaek, 1962) .
Two control blood samples were taken on separate days with the patients either in hospital or outpatients, no dietary advice being given at any stage. They fasted overnight and rested supine for 30 min before the samples were taken between 8.30 a.m. and 9.30 a.m. The specimens were analysed for the various lipids mentioned above, and on one of the two occasions an intravenous glucose tolerance test was performed, blood being taken at the same time for free fatty acid measurements, the sera being frozen until analysis. Treatment was then started with methyldopa and the dose changed to obtain blood pressure control (mean dose 2-2 g; range 1 -25-2-5 g) At this time (mean time after starting drug, 12 weeks; range 6-22 weeks), the lipid studies were again performed under the same conditions as previously described. Following this a diuretic (bendrofluazide 5 mg or 10 mg daily) was added. Four to 16 weeks after this (mean 9 weeks) the lipid measurements were made for a final time with a second intravenous glucose tolerance test. Following these measurements, the serum cholesterol alone was estimated 24-40 weeks (mean 32 weeks) later.
Results
The results are shown in Table 1 . As will be seen, the blood pressure control was good when the patients were on methyldopa alone or in combination with bendrofluazide. The values of the various blood measurements before and during treatment were compared using a paired 't' test. No statistical difference was found between the control lipid measurements nor between the mean control values and those on therapy. The lipoprotein electrophoresis which was quantitated visually also showed no significant changes before or during therapy. The K-value derived from the intravenous glucose tolerance test fell when the patients were taking methyldopa and bendrofluazide. This may represent the diabetogenic effect of thiazide diuretics; Lundbaek (1962) found the K-value to be between 0-20 and 1-02 in a group of diabetics and 0-96 to 3-45 in normals.
The free fatty acids fall during a glucose tolerance test (Hales and Randle, 1963) and this fall did not show any significant change after therapy with methyldopa.
The plasma cholesterol alone was estimated at a mean time of 32 weeks after the final lipid measurements were made, giving a mean value of 212 mg/ 100 ml (s.e.m. 15 mg/100 ml), which did not show a significant change.
Discussion
Hutchinson (1966) found no change in blood lipids in patients treated with methyldopa and a diuretic, but he did not study lipoprotein electrophoretic patterns or use nephelometry. Gross (1965) (Jenkinson, 1973) . We studied three further patients with essential hypertension treated with propranolol and bendrofluazide with an identical experimental protocol. There was no suggestion in any case of a deterioration in blood lipid levels or lipoprotein pattern during effective therapy for several months.
The evidence available suggests that the treatment of hypertension is not associated with significant changes in fasting blood lipids. However, the studies to date have been few, mainly involving methyldopa and diuretics, and over relatively short periods of time. The possibility remains, moreover, that hypotensive therapy predisposes to IHD by some mechanism other than the production of blood lipid abnormalities. It seems likely, however, that increased coronary deaths in treated hypertension merely reflect the reduced incidence of other causes of death in a population with established IHD.
